ArticleMarine biotechnology (New York, N.Y.)2026
Diketopiperazines with In vivo Antimalarial Activity from Sponge-derived Streptomyces sp. 13-12-16.
Article in Marine biotechnology (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Marine microbes are a significant source of natural products (NPs) with marine drug development potential. In this study, we investigated NPs with antimalarial activity from Streptomyces sp. 13-12-16 derived from the sponge Smenospongia aurea aurea. Cyclo [L-Leu-F 4-hydroxy-L-Pro] (Compound A), Cyclo- 4-OH-(L)-Pro-(L)-Phe (Compound B) were isolated from Streptomyces sp. 13-12-16. Plasmodium berghei ANKA (PbA)-infected mice showed a reduction in blood parasitaemia (nearly 20% survival at 12 dpi) and an increase in body weight (60%) in the presence of the compounds Cyclo [L-Leu- 4-hydroxy-L-Pro], Cyclo [4-OH-(L)-Pro-(L)-Phe] (i.e. LK16F3 and LK3-1), the M1 subtype of peritoneal macrophages returned to normal, with an increase in phagocytic capacity and a decrease in pro-inflammatory response. TNFa-l levels were reduced after treatment with compounds LK16F3 and LK3-1, leading to a decrease in inflammation-driven immune responses. Thus, diketopiperazines compounds Cyclo [L-Leu- 4-hydroxy-L-Pro], Cyclo [4-OH-(L)-Pro-(L)-Phe](i.e. LK16F3 and LK3-1) possess enormous potential as antimalarial therapeutic regimens for cerebral malaria infection.
Indexed as
Identifiers
41721892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.